Deisseroth, Hegemann, and Nagel Win Nobel for Optogenetics Breakthrough

Key points

• Karl Deisseroth of Stanford University, Peter Hegemann of Humboldt University of Berlin, and Georg Nagel of the University of Würzburg shared the 2026 Nobel Prize in Physiology or Medicine.
• The prize was awarded for discoveries leading to optogenetics, which allows scientists to switch individual nerve cells on or off using light in a living brain.
• Hegemann and Nagel discovered channelrhodopsin, a light-sensitive protein in algae, while Deisseroth adapted it to control mammalian neurons, enabling precise causal perturbation of brain activity.
• The technique has advanced research into neurological and psychiatric disorders, including Parkinson’s disease and depression, and is being explored in clinical trials to restore vision in patients with retinitis pigmentosa.
• The three laureates will share 12 million Swedish kronor (approximately £900,000) in prize money.

Background

Optogenetics emerged from the discovery of channelrhodopsin in single-celled algae by Hegemann and Nagel in the early 2000s. Deisseroth, who began his lab at Stanford in 2004, was the first to successfully insert this protein into mammalian neurons, allowing researchers to control neural activity with light. Prior to this, brain research relied on imprecise methods like electrical stimulation and drugs, which could not isolate specific circuits. Deisseroth’s work has since expanded to include transparent brain imaging (CLARITY) and real-time human brain data analysis through the Human Neural Circuitry program launched in 2023.

How outlets are covering it

Stanford University emphasized Deisseroth’s role as a 'defining figure' who transformed neuroscience by bridging disciplines and creating tools to unravel brain complexity. The BBC highlighted the Nobel Committee’s praise for revealing how neural circuits underlie memories, feelings, and behaviors, noting the technique’s potential to restore sight in clinical trials. The Washington Post focused on the practical applications, including insights into Alzheimer’s disease and efforts to restore vision, while noting the ages of the laureates: Deisseroth (54), Hegemann (71), and Nagel (73). All sources agree on the core achievement but differ in emphasis: Stanford stresses Deisseroth’s individual impact and mentorship, the BBC focuses on the broader scientific implications, and the Washington Post highlights clinical applications and the collaborative nature of the award.

Why it matters

Optogenetics has revolutionized neuroscience by enabling precise, real-time control of neural activity, allowing researchers to map brain circuits and understand the biological basis of behaviors and disorders. This technology has accelerated research into conditions like Parkinson’s, depression, and Alzheimer’s, and is now being explored in clinical trials to restore vision in patients with retinitis pigmentosa. The award underscores the importance of interdisciplinary collaboration and the potential for translating basic research into medical treatments.

What to watch

Researchers will continue to use optogenetics to map brain circuits and develop treatments for neurological and psychiatric disorders. Clinical trials to restore vision in patients with retinitis pigmentosa are ongoing. Deisseroth plans to use the recognition to advance public understanding of science and the brain, and to support further research into conditions like Parkinson’s, schizophrenia, autism, addiction, depression, and anxiety.